▶ 調査レポート

精密医学の世界市場:成長、動向、予測

• 英文タイトル:Precision Medicine Market - Growth, Trends, and Forecast (2019 - 2024)

Mordor Intelligenceが調査・発行した産業分析レポートです。精密医学の世界市場:成長、動向、予測 / Precision Medicine Market - Growth, Trends, and Forecast (2019 - 2024) / D-MOR01085資料のイメージです。• レポートコード:D-MOR01085
• 出版社/出版日:Mordor Intelligence / 2019年12月26日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥454,750 (USD4,250)▷ お問い合わせ
  Multi User¥508,250 (USD4,750)▷ お問い合わせ
  Global Site License¥802,500 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは精密医学について総合的に分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、技術別(ビッグデータ分析、バイオインフォマティクス、遺伝子配列、創薬、コンパニオン診断、その他)分析、用途別(腫瘍学、CNS、免疫学、呼吸器、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東およびアフリカ、南米)分析、競争状況、市場機会および将来動向に区分して収録しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・精密医学の世界市場:技術別(ビッグデータ分析、バイオインフォマティクス、遺伝子配列、創薬、コンパニオン診断、その他)
・精密医学の世界市場:用途別(腫瘍学、CNS、免疫学、呼吸器、その他)
・精密医学の世界市場:地域別(北米、ヨーロッパ、アジア太平洋、中東およびアフリカ、南米)
・競争状況
・市場機会および将来動向

Precision Medicine Market – Growth, Trends, and Forecast (2019 – 2024)

Market Overview

The global precision medicine market was valued at USD 48,554.1 million in 2018, and is estimated to be valued at USD 84,590.21 million in 2024, witnessing a CAGR of 9.7%. The key factors propelling the growth of this market are increasing online collaborative forums, increasing efforts to characterize genes, and advancements in cancer biology. The fundamental concept of precision medicine is to understand the genetic makeup and difference at a population level, and further at an individual level, in order to customize a drug that targets a particular gene type. Hence, sequencing or characterizing genes is the most important method to gain information about genes and their possible mutations.

The functional characterization of identified genomic mutations, coupled with comprehensive clinical data available in electronic health records, has the potential to provide compelling evidence to implicate novel disease and/or drug-associated mutations in phenotypically well-characterized patients. There have been increasing efforts made by both the government and private players to establish databases that contain information of characterized genes of a large population. Some countries are establishing a national repository of genetic information to accelerate the research in precision medicine. Methods, such as meta-analysis, transcriptome data analysis, and RNA-seq data analysis, are employed to characterize genes, generally.

Scope of the Report

Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention. The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment, and lifestyle, for each person, while developing drugs and vaccines.

Key Market Trends

Oncology is Expected to hold the Highest Market Share in the Application Segment

In the application segment of the precision medicine market, oncology is believed to have the largest market size and is expected to witness a CAGR of 10.3%, during the forecast period.

Precision medicine applications are primarily directed toward better treatment against oncological diseases, with an estimated more than 30% market dominance over other segments. As per the data reported in clinicaltrials.gov, the United States and some European countries are the major hubs for conducting and recruiting patient pool for precision medicine applications in oncology, globally. The high support from the government through funding and rapid growth of genomic analysis are expected to augment the growth of the precision medicine market at a fast rate, over the forecast period.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America currently dominates the market for precision medicine, and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Former President Barack Obama, in 2015, unveiled the Precision Medicine Initiative (PMI), a bold new enterprise to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into every-day clinical practice.

The Precision Medicine Initiative also includes ongoing efforts through the Department of Veteran’s Affairs (VA), which has enrolled over 450,000 veterans in the Million Veteran Program (MVP), a participant-driven research cohort. The Food and Drug Administration (FDA), the Office of the National Coordinator for Health IT, and the Office for Civil Rights announced in February 2016 that they will build research and data capacity, technical tools, and policies to accelerate precision medicine, thereby, boosting the precision medicine market in the country.

Competitive Landscape

The precision medicine market is highly competitive and consists of several major players, along with a number of smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with affordable prices. Companies, like Medtronic PLC, Pfizer Inc., Novartis AG, Qiagen, and Teva Pharmaceuticals, hold substantial shares in the market.

Reasons to Purchase this report:

The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Online Collaborative Forums
4.2.2 Increasing Efforts to Characterize Genes
4.2.3 Advancement in Cancer Biology
4.3 Market Restraints
4.3.1 Perils of Data Sharing
4.3.2 Shift From Treatment-based To Preventive Healthcare
4.3.3 Declining Trends in FDA Pharmacotherapy Approval Rate
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Big Data Analytics
5.1.2 Bioinformatics
5.1.3 Gene Sequencing
5.1.4 Drug Discovery
5.1.5 Companion Diagnostics
5.1.6 Other Technologies
5.2 By Application
5.2.1 Oncology
5.2.2 CNS
5.2.3 Immunology
5.2.4 Respiratory
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocrates Life Sciences AG
6.1.2 Nanostring Technologies
6.1.3 Intomics
6.1.4 Pfizer Inc.
6.1.5 Eagle Genomics Ltd
6.1.6 Teva Pharmaceutical Industries Ltd
6.1.7 Laboratory Corporation Of America Holdings
6.1.8 Medtronic
6.1.9 Novartis AG
6.1.10 Qiagen NV
6.1.11 Quest Diagnostics Incorporated
7 MARKET OPPORTUNITIES AND FUTURE TRENDS